16 terminated. 16 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Terminated 16 |
| Phase 2 | 1 | Terminated 1 |
Follow Pulmonary Fibrosis: new trials by email Literature Review of Pulmonary Fibrosis trials Research Report on Pulmonary Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis PRM-151 (Zinpentraxin Alfa) - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Hoffmann-La Roche | 117 | 2021-08-30 | 2024-05-16 |
| A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis PRM-151 (Zinpentraxin Alfa), Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Hoffmann-La Roche | 665 | 2021-03-19 | 2024-04-18 |
| A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension INOpulse®, Placebo, Open Label Extension - Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Terminated | Bellerophon Pulse Technologies | 145 | 2020-12-14 | 2023-07-27 |
| Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Pamrevlumab, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Kyntra Bio | 372 | 2020-09-30 | 2024-08-12 |
| Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Pamrevlumab, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Kyntra Bio | 393 | 2019-06-18 | 2024-09-19 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 525 | 2018-11-28 | 2022-07-29 |
| A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care GLPG1690, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Lakefront Biotherapeutics NV | 781 | 2018-11-05 | 2022-07-29 |
| CleanUP IPF for the Pulmonary Trials Cooperative Antimicrobial therapy: Co-trimoxazole or Doxycycline, No Intervention: Standard of Care - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Weill Medical College of Cornell University | 513 | 2017-03-22 | 2021-04-08 |
| Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole Cotrimoxazole, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 3 | 2013-11-25 | 2017-11-14 |
| AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis warfarin, placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Duke University | 145 | 2009-10-01 | 2014-07-23 |
| Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Sildenafil, Losartan, Sildenafil and Losartan - Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis | Phase 2 / Phase 3 | Terminated | Alicia Gerke | 12 | 2009-09-01 | 2018-11-13 |
| ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis Ambrisentan, Placebo - Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension | Phase 3 | Terminated | Gilead Sciences | 40 | 2009-07-01 | 2014-05-15 |
| (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF Ambrisentan, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Terminated | Gilead Sciences | 494 | 2008-12-01 | 2014-04-08 |
| The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) Interferon gamma-1b ("Actimmune") - Idiopathic Pulmonary Fibrosis, Lung Disease | Phase 3 | Terminated | InterMune | 826 | 2003-12-01 | 2009-07-02 |
| An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF Interferon gamma-1b - Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis | Phase 3 | Terminated | InterMune | 91 | 2003-11-01 | 2007-11-06 |
| A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone interferon-gamma 1b, azathioprine - Lung Disease, Pulmonary Fibrosis | Phase 3 | Terminated | InterMune | 2002-04-01 | 2007-11-06 |
Idiopathic Pulmonary Fibrosis (15) · Lung Diseases (3) · Lung Diseases, Interstitial (3) · Fibrosis (2) · Hypertension, Pulmonary (2) · Idiopathic Interstitial Pneumonias (2)
Respiratory Tract Diseases (16) · Lung Diseases (13) · Lung Diseases, Interstitial (13) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Fibrosis (6) · Cardiovascular Diseases (2) · Hypertension (2) · Vascular Diseases (2)
GLPG1690 (2) · PRM-151 (2) · ambrisentan (2) · interferon gamma-1b (2) · pamrevlumab (2) · Azathioprine (1) · Doxycycline (1) · Interferon-gamma (1) · Losartan (1) · Sildenafil Citrate (1) · Sugars (1) · Trimethoprim, Sulfamethoxazole Drug Combination (1) · Warfarin (1)
InterMune (3) · Gilead Sciences (2) · Hoffmann-La Roche (2) · Kyntra Bio (2) · Lakefront Biotherapeutics NV (2) · Alicia Gerke (1) · Bellerophon Pulse Technologies (1) · Duke University (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Weill Medical College of Cornell University (1)
United States (14) · Germany (7) · Italy (7) · Argentina (6) · Australia (6) · Canada (6) · Spain (6) · Czechia (5) · France (5) · Mexico (5) · Netherlands (5) · Poland (5) · South Korea (5) · United Kingdom (5) · Belgium (4)
Ganesh Raghu, MD (2) · Alicia K Gerke, MD (1) · Ashika Ahmed (1) · Danielle Antin-Ozerkis, MD (1) · Fernando Martinez, MD (1) · Fernando Martinez, MD, MS (1) · Gail Weinmann, MD (1) · Galen Toews, MD (1) · Hunter Gillies, M.D. (1) · Imre Noth, MD (1)
PMID 31179008, PMID 35688625, PMID 36724330, PMID 37159034, PMID 38288082, PMID 19570573, PMID 22561965, PMID 23648946, PMID 24177001, PMID 24311766, PMID 24717624, PMID 25613108, PMID 25890798, PMID 26111071, PMID 28657784, PMID 31047956, PMID 32164673, PMID 33434107, PMID 33974018, PMID 34662125, PMID 35204752, PMID 38030064, PMID 38238788, PMID 38354066, PMID 38762797, PMID 39141673, PMID 39761005
2018 (2), U01HL128954 (1), U10HL080413 (1)